Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: NMN evidence and protocol review
Also known as: Nicotinamide mononucleotide
Nicotinamide mononucleotide (NMN) is a direct NAD+ precursor. Human trials from 2023-2024, including an 8-week Japanese study (11 healthy middle-aged men, 250mg/day) and a randomized multicenter dose-ranging trial (GeroScience, 2023), confirm that oral NMN supplementation (100-1,250 mg/day studied) reliably raises blood/PBMC NAD+ levels and is generally well tolerated with no serious adverse events reported across completed trials (durations 3-12 weeks). Functional/clinical outcome data (cognitive, physical performance) remain more limited and variable, and individual response depends on baseline NAD+ status, gut microbiota, and cellular uptake pathways. The FDA moved to classify NMN as excluded from the dietary supplement definition (due to prior IND status) in 2023, complicating its US regulatory status - verify current FDA guidance before treating as a standard supplement.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.
250 mg/day
Context: randomized human metabolic study
Formulation: Oral-mucosal formulations are not dose-equivalent to injectable or topical formulations.
Route safety: Research-study protocol only; it is not an approved or individualized instruction and should not be extrapolated to another route.
Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.
Human studies are small and heterogeneous; biomarker changes do not establish broad anti-aging efficacy.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention NMN or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.